drugset / Trial / NCT07402343
Tarlatamab for SCLC Brain Metastases
Phase 2
Not yet recruiting
35 enrolled
Maastricht University Medical Center
Erasmus Medical Center · collabThe Netherlands Cancer Institute · collabUniversity Medical Center Groningen · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Timeline
- Start
- 2026-05
- Primary completion
- 2029-02
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | 10 mg | Intravenous |